Nonclinical Efficacy Testing » Non-Clinical CROs and Agencies » Mediford Corporation

Mediford Corporation

Table of Contents
Table of Contents

Mediford offers a comprehensive range of non-clinical research services, including various safety studies required for regulatory submissions, pharmacology and pharmacokinetics studies. This page provides an overview of the key features of Mediford’s non-clinical service capabilities, examples of disease models, and representative study cases. It is intended to serve as a reference for selecting a CRO.

Features of Mediford’s Contract Non-Clinical Research Services

Extensive Study Portfolio

Mediford provides a wide variety of non-clinical studies, including pharmacology, safety, and pharmacokinetics studies. The company offers end-to-end support—from exploratory screening and new modality evaluation to transition into clinical development and regulatory submission. They offer flexible and efficient study execution with their dedicated project management system.

Highly Qualified Specialists

Mediford has JSTP/ JCVP-certified specialists in toxicology and pathology, as well as veterinarians, pharmacists, laboratory animal technologists, and JSOT-certified toxicologists. Their expertise enables high-quality data generation and supports establishing new evaluation protocols for emerging modalities and novel therapeutic concepts.

Commitment to Animal Welfare

All studies follow the 3Rs (Replacement, Reduction, Refinement) principles. Mediford implements microsampling techniques to analyze drug concentrations with minimal blood volume, reducing the number of animals required. The company is fully cerfitied by AAALAC International.

Infectious Disease Model Development and Evaluation

With ABSL2 and BSL2 facilities, Mediford conducts the full spectrum of infectious disease studies—from establishing a new model with viruses, bacteria, and fungi to efficacy and vaccine evaluation. Experienced researchers will deliver timely and reliable data to support your needs.

Examples of Disease Models Offered by Mediford

It is essential to go through the testing of candidate compounds in animal models that reproduce the target disease before advancing to clinical trials.

However, clinically relevant disease models may not always exist, thus there are demands for animal models with strong clinical correlation.

Below are some examples of disease models offered at Ina Research.

LPS-Induced Depression Model

A depression model is induced by administering lipopolysaccharide (LPS) to mice. Antidepressant effects can be evaluated by behavioral tests(forced swim, tail suspension, where immobility time serves as an indicator.)

Post-Stroke Pain Model

Post-stroke central pain is a persistent and debilitating complication of stroke. In this model, collagenase IV is microinjected into the ventral posterolateral nucleus of the thalamus in SD rats to induce intracerebral hemorrhage and reproduce CPSP pathology.

PDX Model (Oncology)

The PDX (Patient-Derived Xenograft) model is established by transplanting patient-derived tumor tissue into immunodeficient mice. Because tumor characteristics such as genetic mutations and microenvironment are preserved, PDX models are widely used in efficacy testing of anticancer and molecular-targeted therapies, as well as personalized medical research.

Reference: Mediford Official Website(https://www.mediford.com/service/topics/pdx/)

Ischemic Heart Disease Model

Myocardial infarction models in rats and mice are created by temporarily occluding and reopening the coronary artery to reproduce ischemia–reperfusion injury. Cardiac function is assessed using high-resolution ultrasound imaging (Vevo F2), allowing non-invasive analysis of left ventricular ejection fraction and wall motion.

GVHD Model

The graft-versus-host disease (GVHD) model reproduces the pathology in which donor immune cells attack host tissues after hematopoietic stem cell transplantation. The model is widely used to evaluate immunosuppressants and cell-based therapies.

Mediford’s Non-Clinical Study Examples

Neuropathic Pain Model Development

Neuropathic pain is a chronic condition caused by peripheral or central nerve injury. Mediford has extensive experience with the Bennett (thermal, mechanical, cold stimuli), Chung (thermal, mechanical), and Seltzer (thermal, mechanical) models, enabling reliable and reproducible pharmacology studies.

Skin Permeability Test in Compliance with GLP for Pesticides

In vitro skin permeability studies evaluate the penetration and transdermal transfer of test substances using human or animal skin. When combined with in vivo rat dermal administration studies, human in vivo absorption rates can also be estimated. Study results required for pesticide registration, including re-evaluation, are generated under pesticide GLP standards.

Company Information

Mediford provides medical writing services and contract research services, which utilize wide range of pathological models. They have decades of experience in non-clinical research.

Address 36-1 Shimizu-cho, Itabashi-ku, Tokyo
Tel 03-5943-9270
Website https://www.mediford.com/

3 Recommended Contract Research Organizations
for Non-Clinical Studies
— by Target goal and Expertise

In non-clinical development, the choice of contract research organization shapes the quality of the data and the time it takes to reach the next decision. Below, three CROs are introduced by the type of study they support: pharmacology (efficacy) studies, safety studies, and pharmacokinetic (PK/PD) studies. Each summary describes the services the company offers so that you can match a provider to your target and development objective.

Pharmacology (Efficacy) StudiesDisease-Relevant Models for
Translational Drug Evaluation
SMC Laboratories, Inc.
Reference: SMC Laboratories, Inc. official website (https://www.smccro-lab.com/)

SMC Laboratories, Inc.

SMC Laboratories is a specialized non-clinical CRO focused on in vivo pharmacology and efficacy studies using disease-relevant animal models, particularly in fibrosis, inflammation, metabolic diseases, and oncology.

Areas of Expertise
Disease-Relevant Model Portfolio

SMC Laboratories offers models covering the liver, lung, kidney, intestine, and oncology. Its portfolio includes the proprietary STAM™ model for MASH, fibrosis, and hepatocellular carcinoma.

Study Design Based on Target Biology

Study plans are developed around the target biology, mechanism of action, disease stage, and development objective. Pharmacological endpoints can be combined with histopathology, biomarkers, and disease-specific readouts.

Support from Target Validation to Proof of Concept

With experience from more than 1,000 studies for clients in 30 countries, SMC Laboratories supports programs from target validation and candidate selection through in vivo proof-of-concept studies.

Safety StudiesComprehensive Safety Assessment for
Preclinical Development
Charles River Laboratories
Reference: Charles River Laboratories official website (https://www.criver.com/)

Charles River Laboratories

Charles River provides non-clinical toxicology and safety assessment services for programs ranging from exploratory safety studies to IND-enabling development.

Areas of Expertise
General Toxicology Across Study Designs

Services include single- and repeat-dose toxicology, dose-range finding, and general toxicology studies across multiple species and administration routes.

Non-GLP and GLP Study Support

Charles River supports both non-GLP and GLP studies, allowing sponsors to progress from early safety characterization to studies intended for regulatory submissions.

Integrated IND-Enabling Safety Assessment

Toxicology studies can be integrated with toxicokinetics, clinical pathology, histopathology, and safety pharmacology to support interpretation and IND-enabling safety packages.

Pharmacokinetic (PK/PD) StudiesConnecting Drug Exposure with
Pharmacological Response
Inotiv
Reference: Inotiv official website (https://www.inotiv.com/)

Inotiv

Inotiv provides integrated PK/PD, DMPK, and bioanalytical services to characterize drug exposure and its relationship with pharmacological response.

Areas of Expertise
Pharmacokinetic Characterization

PK studies characterize exposure, half-life, clearance, and other pharmacokinetic parameters needed to understand how a candidate behaves in the selected model.

Exposure–Response Evaluation

Pharmacokinetic data can be combined with pharmacodynamic endpoints and bioanalysis to evaluate the relationship between drug exposure and pharmacological response.

Integrated DMPK and Development Support

Integrated DMPK, pharmacology, and safety information supports candidate comparison, dose selection, dosing-frequency optimization, and decisions about subsequent preclinical development.

By Therapeutic Area
Disease Animal Models
and Reviews
Proven Capability, Expertise and Track Record
Top 3 Non-Clinical CRO Services